from the Utrecht Medical Centre in The Netherlands provides the first clinical evidence, to the authors' knowledge, that local interleukin-2 (IL-2) therapy in combination with radiotherapy is an ...
Despite the challenges, there's still plenty of interest in IL-2 as a cancer therapy, with several companies, including Medicenna, Anaveon, Cue Biopharma, Aulos Bioscience, and Synthekine in ...